Fact CheckerSign in

NCT04572958Active, not recruiting

Changes in iOS in IPF

Changes in Impulse Oscillometry Measurements and Outcomes in Idiopathic Pulmonary Fibrosis

Source: ClinicalTrials.gov · Last updated 5 May 2022

Brief summary (registry, in English)

Idiopathic pulmonary fibrosis (IPF) is a condition where scar tissue (called fibrosis) builds up in the lungs. It usually gets worse over time. Fibrosis causes the lungs to become stiff, and reduces the amount of oxygen that the lungs can take up. People with IPF complain of worsening breathlessness, which limits their day to day activities. Lung function tests are breathing tests that measure how well your lungs are working, and are used by doctors to decide whether to start or stop medicines in people with IPF. However, people with IPF tell us that lung function tests require a lot of effort, can make them cough and feel very short of breath. About 1 in 5 people with IPF are unable to perform lung function results accurately. This might unfairly lead to some people with IPF not receiving the right medications or for their medications to be stopped too soon. Impulse oscillometry (iOS) uses sound waves to measure the stiffness of the lung, and has been used successfully in children who are unable to perform normal lung function tests. The overall aim of the research is to see whether changes in iOS measures can give useful information about the lungs in patients with IPF; for example, by judging the overall impact of the disease on the lungs, or predicting future deterioration. We will look at how iOS changes over time in patients with IPF, and to see whether these measurements can tell us about whether IPF is getting worse or predict important health events, such as hospital admission. We will compare change in iOS with changes in other tests used to monitor IPF and with patient reported ratings of change in their condition. This will help decide the amount of iOS change that is noticed and considered meaningful by people with IPF.

Status (registry)
Active, not recruiting
Study type
Observational
Enrollment
132 (actual)
First submitted
26 Sept 2020
Start date
6 Nov 2020
Primary completion date
5 May 2022
Lead sponsor
Royal Brompton & Harefield NHS Foundation Trust
NCT number
NCT04572958

What you commit to

  • Study type: Observational
  • Participants enrolled: 132
  • From 6 Nov 2020 to the primary completion date, 5 May 2022
  • 1 site in 1 country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Other illness

  • Contraindication to performing conventional lung function tests, e.g untreated TB, haemoptysis, pneumothorax, unstable cardiovascular status, recent eye, thoracic or abdominal surgery, thoracic, abdominal or cerebral aneurysm, acute illness (including diarrhoea and vomiting).

Other

  • Unable to create seal on mouthpiece

Who the study is looking for

  • Diagnosis of idiopathic pulmonary fibrosis made by specialist multidisciplinary team according to international standards
  • Able to provide written informed consent

Age in the registry: 18 years to 100 years · Sex: All

Full criteria on ClinicalTrials.gov

Sites (1)

Sites in registry order. Pick your city on the disease page to sort them by distance.

SiteCityCountrySite status
Royal Brompton and Harefield Hospitals
Coordinator of this site? Confirm its status
LondonUnited KingdomUnknown status

This page is information, not medical advice. Discuss any trial with your doctor.